866763-17-9

Upstream product

• 2252-51-9 2-choro-4-fluorobenzoic acid 
• 264927-50-6 2-chloro-5-(chlorosulfonyl)-4-fluorobenzoic acid 

Downstream Products

• 866764-23-0 4-chloro-5-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-ylcarbamoyl)-2-fluoro-benzenesulfonyl chloride 
• 1235560-83-4 (R)-4-chloro-2-fluoro-N-(2-fluorophenyl)-N-methyl-5-(octahydropyrrolo[1,2-a]pyrazine-2-carbonyl)benzenesulfonamide 
• 1235560-28-7 ABT-639 
• 669072-43-9 2-chloro-N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-4-fluoro-5-(morpholine-4-sulfonyl)-benzamide 

Relevant academic research and scientific papers

CYCLIC INHIBITORS OF HEPATITIS B VIRUS

The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing said compounds.

INHIBITORS OF HEPATITIS B VIRUS

The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditio

Optimization of ADME Properties for Sulfonamides Leading to the Discovery of a T-Type Calcium Channel Blocker, ABT-639

The discovery of a novel peripherally acting and selective Cav3.2 T-type calcium channel blocker, ABT-639, is described. HTS hits 1 and 2, which have poor metabolic stability, were optimized to obtain 4, which has improved stability and oral bi

NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS

The present application relates to calcium channel inhibitors comprising compounds of formula (I), formula (II), formula (III), or formula (IV), wherein L1, R1, R2, R3, R4, R5, R6, R7 and Rc are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Site-specific covalent labeling of His-tag fused proteins with a reactive Ni(ii)-NTA probe

A new method for covalent labeling of a His-tag fused protein with a small reactive probe was developed; this method is based on the complementary interaction between the His-tag and Ni(ii)-NTA, which facilitates a nucleophilic reaction between a histidin

Structure-activity relationships of novel potent MurF inhibitors

A novel class of MurF inhibitors was discovered and structure-activity relationship studies have led to several potent compounds with IC 50=22～70 nM. Unfortunately, none of these potent MurF inhibitors exhibited significant antibacterial activity even in the presence of bacterial cell permeabilizers.